Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
ERS Genomics
ERS Genomics
Activities:
Manufacturing
Research & Development
Analysis
X
LinkedIn
Trending Articles
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
US court lifts modified consent decree on Xellia’s Cleveland facility
The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
Lonza's AI-enabled small molecule development tool launches
The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Autoscribe Informatics’ new Australia office supports business growth
The company's move to West Lakes Adelaide expands its ability to service the Asia Pacific region in digitalising laboratory information
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Cell & Gene Therapy
CRISPR patent upheld by CNIPA
Patent CN201380038920.6 was upheld by the China National Intellectual Property Administration (CNIPA) in response to an invalidation challenge
Regulatory
Key Charpentier/Doudna CRISPR patent upheld by Japanese Patent Office
Patent JP6692856 upheld for second time in response to invalidation challenge
Research & Development
CET licenses CRISPR/Cas9 portfolio from ERS Genomics
ERS was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr Emmanuelle Charpentier
Finance
ERS Genomics and Japan SLC sign CRISPR/Cas9 license agreement
ERS Genomics holds an exclusive license from Dr Emmanuelle Charpentier to the foundational intellectual property covering CRISPR/Cas9 for use as a research platform
Regulatory
ERS Genomics and Nippon Gene sign CRISPR/Cas9 license agreement
ERS Genomics holds the exclusive license from co-founder Dr Emmanuelle Charpentier to the foundational intellectual property covering CRISPR/Cas9 for use as a research platform
Regulatory
ERS Genomics licenses CRISPR gene editing tech to Otsuka
Summit Pharmaceuticals International Corporation, a subsidiary of Sumitomo Corporation, serves as the exclusive agent for ERS Genomics in Japan
Finance
ERS Genomics appoints Jon Kratochvil as VP Business Development
He is an inventor on more 40 patents and patent applications
Subscribe now